Pharmacologic inhibition of PI3K p110δ in mutant Shp2E76K-expressing mice.

about

Pharmacologic inhibition of PI3K p110δ in mutant Shp2E76K-expressing mice.

Item

http://www.wikidata.org/entity/Q47105237

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Pharmacologic inhibition of PI3K p110δ in mutant Shp2E76K-expressing mice.

@en

Pharmacologic inhibition of PI3K p110δ in mutant Shp2E76K-expressing mice.

@nl

type

Item

label

Pharmacologic inhibition of PI3K p110δ in mutant Shp2E76K-expressing mice.

@en

Pharmacologic inhibition of PI3K p110δ in mutant Shp2E76K-expressing mice.

@nl

prefLabel

Pharmacologic inhibition of PI3K p110δ in mutant Shp2E76K-expressing mice.

@en

Pharmacologic inhibition of PI3K p110δ in mutant Shp2E76K-expressing mice.

@nl

P1476

Pharmacologic inhibition of PI3K p110δ in mutant Shp2E76K-expressing mice.

@en

P2093

Elizabeth L Virts

http://www.w3.org/2001/XMLSchema#string

Lisa Deng

http://www.w3.org/2001/XMLSchema#string

Rebecca J Chan

http://www.w3.org/2001/XMLSchema#string

Reuben Kapur

http://www.w3.org/2001/XMLSchema#string

P2860

PI3K p110δ uniquely promotes gain-of-function Shp2-induced GM-CSF hypersensitivity in a model of JMML.

PI3Kδ inhibition elicits anti-leukemic effects through Bim-dependent apoptosis

Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia.

Non-lineage/stage-restricted effects of a gain-of-function mutation in tyrosine phosphatase Ptpn11 (Shp2) on malignant transformation of hematopoietic cells.

Human somatic PTPN11 mutations induce hematopoietic-cell hypersensitivity to granulocyte-macrophage colony-stimulating factor.

Targeting the PI3K/Akt pathway in murine MDS/MPN driven by hyperactive Ras.

Non-hematopoietic stem cell transplantation treatment of juvenile myelomonocytic leukemia: a retrospective analysis and definition of response criteria.

Hematopoietic stem cell transplantation (HSCT) in children with juvenile myelomonocytic leukemia (JMML): results of the EWOG-MDS/EBMT trial.

The PI3K Pathway in Human Disease.

The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer.

P304

84776-84781

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.21455

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-10-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29156682

http://www.w3.org/2001/XMLSchema#string

P932

5689572

http://www.w3.org/2001/XMLSchema#string